Online
| Post a Message | Explore Forums | Browse Stock Messages | Hot Discussions | Top rated Messages | Top Boarders | |
|
|
|
Sun Pharmaceutical Industries
Take profit in sunpharma,down target=940
Posted by :
marketmanTracked by: 0 Boarder
Fiis and domestic funds may agggressively take profits in the counter due to over all bearishness in the market.......
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
Though its OPM is the best in the industry,the latest litigations by USFDA my trouble the US income.... caraco and taro issues are concerns at the moment.... 
NSE Announcements on Sun Pharma
Posted by : MMB MessengerTracked by: 0 Boarder
Sun Pharmaceuticals Industries Ltd has informed the Exchange regarding the press release dated November 07, 2008, titled "Sun Pharmaceutical Extends Tender Offer for Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
BSE Announcements on Sun Pharma
Posted by : MMB MessengerTracked by: 0 Boarder
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated November 07, 2008 titled "Sun Pharmaceutical Extends Tender Offer for Taro"...
BSE Announcements on Sun Pharma
Posted by : MMB MessengerTracked by: 0 Boarder
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated November 05, 2008 titled "Sun Pharmaceutical announces USFDA approval to market generic Sinemet tablets"...
NSE Announcements on Sun Pharma
Posted by : MMB MessengerTracked by: 0 Boarder
Sun Pharmaceuticals Industries Ltd has informed the Exchange regarding a press release dated November 05, 2008, titled "Sun Pharmaceutical announces USFDA approval to market generic Sinemet(R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
Take profit in sunpharma,down target=940
Posted by : marketmanTracked by: 0 Boarder
Though its OPM is the best in the industry,the latest litigations by USFDA my trouble the US income.... caraco and taro issues are concerns at the moment.......
In reply to:
Take profit in sunpharma,down target=940
Posted by : sambala
Sun Pharma: Cloudy weather
The financial impact of the US FDA warning should not be severe. However, the firm needs to ensure that the issues are sorted out.
It’s unfortunate that the US FDA has sent out warning letters to Caraco, a subsidiary of Sun Pharma. The management, however, says that would not disrupt sales though the FDA may withhold approval of pending new drug applications. That could hamper the pipeline; of the 96 ANDAs (abbreviated new drug applications) awaiting approval, 19 are from Caraco. Industry watchers believe that there shouldn’t be any serious financial implications though they are a tad anxious.
Meanwhile, Sun Pharma’s sales in the September 2008 quarter were up a robust 76 per cent y-o-y to Rs 1,178 crore driven by some brisk business in US formulations — Caraco itself grew 197 per cent y-o-y to $122 million. Drugs that sold well were generic Pantoprazole (used to treat ulcers in the oesophagus) and Ethyol ( an injection used prior to cancer treatment) and together they contributed around $70-80 million of the sales of US formulations. These two drugs, the company says, will not be impacted by the FDA enquiry.
But Sun has to contend with the ongoing legal tussle with Wyeth over generic Pantoprazole which it continues to sell ‘at risk’ probably because the product fetches high gross margins estimated at around 80 per cent. Sun is making the most of rival Teva having exited the market ; as of now it’s just Sun and Wyeth, which has an authorised generic, who continue to sell Pantoprazole. Should Wyeth win the case, Sun could be saddled with damages.
Sun has done well in the home market too, turning in a revenue growth of 20 per cent. However, the operating profit margin (OPM), at nearly 46 per cent — up by close to1300 basis points —disappointed analysts who had pencilled in higher margins expecting better realisations from Para IV drugs — products that are sold exclusively by generics players for a certain period of time.The net profit, though, grew 124 per cent to Rs 490 crore, partly boosted by higher other income. Sun should end FY09 with revenues close to Rs 4,300 crore and a net profit of Rs 1,800 crore . However, the litigation on various fronts, including that for Taro, is worrying.
BY Shobhana Subramanian & Varun Sharma
Take profit in sunpharma,down target=940
Posted by : sambalaTracked by: 0 Boarder
Sun Pharma: Cloudy weather
The financial impact of the US FDA warning should not be severe. However, the firm needs to ensure that the issues are sorted out.
It’s unfortunate that the US FDA has sent out warning letters to Caraco, a subsidiary of Sun Pharma. The management, however, says that would not disrupt sales though the FDA may withhold approval of pending new drug applications. That could hamper the pipeline; of the 96 ANDAs (abbreviated new drug applications) awaiting approval, 19 are from Caraco. Industry watchers believe that there shouldn’t be any serious financial implications though they are a tad anxious.
Meanwhile, Sun Pharma’s sales in the September 2008 quarter were up a robust 76 per cent y-o-y to Rs 1,178 crore driven by some brisk business in US formulations — Caraco itself grew 197 per cent y-o-y to $122 million. Drugs that sold well were generic Pantoprazole (used to treat ulcers in the oesophagus) and Ethyol ( an injection used prior to cancer treatment) and together they contributed around $70-80 million of the sales of US formulations. These two drugs, the company says, will not be impacted by the FDA enquiry.
But Sun has to contend with the ongoing legal tussle with Wyeth over generic Pantoprazole which it continues to sell ‘at risk’ probably because the product fetches high gross margins estimated at around 80 per cent. Sun is making the most of rival Teva having exited the market ; as of now it’s just Sun and Wyeth, which has an authorised generic, who continue to sell Pantoprazole. Should Wyeth win the case, Sun could be saddled with damages.
Sun has done well in the home market too, turning in a revenue growth of 20 per cent. However, the operating profit margin (OPM), at nearly 46 per cent — up by close to1300 basis points —disappointed analysts who had pencilled in higher margins expecting better realisations from Para IV drugs — products that are sold exclusively by generics players for a certain period of time.The net profit, though, grew 124 per cent to Rs 490 crore, partly boosted by higher other income. Sun should end FY09 with revenues close to Rs 4,300 crore and a net profit of Rs 1,800 crore . However, the litigation on various fronts, including that for Taro, is worrying.
BY Shobhana Subramanian & Varun Sharma...
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
USFDA restrictions on its US subsidiary dampening the sentiment in the counter.... near term FDA approvals may be delayed....
Take profit in sunpharma,down target=940
Posted by : marketmanTracked by: 0 Boarder
USFDA restrictions on its US subsidiary dampening the sentiment in the counter.... near term FDA approvals may be delayed.......
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
As expected earlier.people took profits in the counter to bring it down to tripple digit mark.... US subsidiary caraco is said to be facing FDA problems....
Take profit in sunpharma,down target=940
Posted by : RamkiTracked by: 0 Boarder
Yeah...U are absolutely right...But the problem is these FDA problems seem to be exaggerated only to pick this stock at lower levels....ROFL...
In reply to:
Take profit in sunpharma,down target=940
Posted by : jdosvd
Sun Pharma was shining as it declared superb results and brokerages correctly gave a `buy`on this stock with runaway targets!! Also last two days were great for the markets as they went firmly upwards!
However what surprised so many was the was Sun Pharma saw pronounced selling in these rising markets and with these excellent results buying the stock seemed a bargain..............then came the news of Caraco in serious problems with the FDA and in the wake of the news the already beaten stock is falling strongly today! Just see what Powerful Insider Trading before the news of Caraco was made public.
Same was recently observed on the counters of Suzlon/IVCRL/Ranbaxy etc etc.before price-sensitive information/results was made public.SEBI or the exchanges just appear to be unalert!??
Take profit in sunpharma,down target=940
Posted by : jdosvdTracked by: 0 Boarder
Sun Pharma was shining as it declared superb results and brokerages correctly gave a `buy`on this stock with runaway targets!! Also last two days were great for the markets as they went firmly upwards!
However what surprised so many was the was Sun Pharma saw pronounced selling in these rising markets and with these excellent results buying the stock seemed a bargain..............then came the news of Caraco in serious problems with the FDA and in the wake of the news the already beaten stock is falling strongly today! Just see what Powerful Insider Trading before the news of Caraco was made public.
Same was recently observed on the counters of Suzlon/IVCRL/Ranbaxy etc etc.before price-sensitive information/results was made public.SEBI or the exchanges just appear to be unalert!??...
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
As expected earlier.people took profits in the counter to bring it down to tripple digit mark.... US subsidiary caraco is said to be facing FDA problems....
Take profit in sunpharma,down target=940
Posted by :
jogayakTracked by: 0 Boarder
The company is very strong and so is the scripts movement. They do not have any major issues with FDA, so I dont think it would remain at this level for long. SunPharma always hovers around the 1200-400 mark....
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
As expected earlier.people took profits in the counter to bring it down to tripple digit mark.... US subsidiary caraco is said to be facing FDA problems....
Take profit in sunpharma,down target=940
Posted by : marketmanTracked by: 0 Boarder
As expected earlier.people took profits in the counter to bring it down to tripple digit mark.... US subsidiary caraco is said to be facing FDA problems.......
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
Investors continueing take profits in the counter....
Take profit in sunpharma,down target=940
Posted by : marketmanTracked by: 0 Boarder
Investors continueing take profits in the counter.......
In reply to:
Take profit in sunpharma,down target=940
Posted by : marketman
Fiis babus and domestic funds taking cash out from the counter....
Brokerages say Buy.
Posted by :
GoodMan..Tracked by: 0 Boarder
This stock is going southwards even when there is good sentiment... Are there any specific reason? OR MFs are doing profit booking.....
In reply to:
Brokerages say Buy.
Posted by : satcy
Angel Broking: Buy for a target of 1600
Karvy: Buy for a target of 1537
BNP Pariba: Buy for a target of 1695
1000 is a pretty good support for the stock. RBI`s rate cut today should spark a rally on Monday. Might just be the beginning of a rebound for the markets, Sun Pharma should make a good buy.
Brokerages say Buy.
Posted by : satcyTracked by: 0 Boarder
Angel Broking: Buy for a target of 1600
Karvy: Buy for a target of 1537
BNP Pariba: Buy for a target of 1695
1000 is a pretty good support for the stock. RBI`s rate cut today should spark a rally on Monday. Might just be the beginning of a rebound for the markets, Sun Pharma should make a good buy....
Boarders Outlook on Sun Pharma
positive outlook1 queries on Sun Pharma
More from the Pharmaceuticals Sector
see moreBoarders tracking Sun Pharma
News Updates on Sun Pharma
